BR112014002718A8 - célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal - Google Patents

célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal

Info

Publication number
BR112014002718A8
BR112014002718A8 BR112014002718A BR112014002718A BR112014002718A8 BR 112014002718 A8 BR112014002718 A8 BR 112014002718A8 BR 112014002718 A BR112014002718 A BR 112014002718A BR 112014002718 A BR112014002718 A BR 112014002718A BR 112014002718 A8 BR112014002718 A8 BR 112014002718A8
Authority
BR
Brazil
Prior art keywords
cell
kit
treatment
pharmaceutical composition
retinal degeneration
Prior art date
Application number
BR112014002718A
Other languages
English (en)
Other versions
BR112014002718A2 (pt
Inventor
Sanges Daniela
Pia Cosma Maria
Original Assignee
Sanges Daniela
Pia Cosma Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanges Daniela, Pia Cosma Maria filed Critical Sanges Daniela
Publication of BR112014002718A2 publication Critical patent/BR112014002718A2/pt
Publication of BR112014002718A8 publication Critical patent/BR112014002718A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112014002718A 2011-08-05 2012-08-06 célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal BR112014002718A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (2)

Publication Number Publication Date
BR112014002718A2 BR112014002718A2 (pt) 2017-06-13
BR112014002718A8 true BR112014002718A8 (pt) 2017-06-20

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002718A BR112014002718A8 (pt) 2011-08-05 2012-08-06 célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal

Country Status (15)

Country Link
US (1) US20140199277A1 (pt)
EP (2) EP2554662A1 (pt)
JP (1) JP2014527407A (pt)
KR (1) KR20140068936A (pt)
CN (1) CN104011203A (pt)
AR (1) AR087471A1 (pt)
AU (1) AU2012293681A1 (pt)
BR (1) BR112014002718A8 (pt)
CA (1) CA2844106A1 (pt)
CO (1) CO7081142A2 (pt)
IL (1) IL230830A0 (pt)
MX (1) MX2014001475A (pt)
RU (1) RU2014108478A (pt)
SG (1) SG2014008080A (pt)
WO (1) WO2013020945A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003692A (es) * 2011-09-29 2015-03-20 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Composiciones y métodos para el tratamiento de condiciones degenerativas retinianas.
KR102368751B1 (ko) 2014-01-17 2022-03-03 스미또모 가가꾸 가부시끼가이샤 모양체 주연부 간세포의 제조 방법
US10821193B2 (en) * 2014-09-16 2020-11-03 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (MYOC) glaucoma
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
CA3032153A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
JP6779546B2 (ja) * 2016-11-06 2020-11-04 ナノスコープ テクノロジーズ エルエルシーＮａｎｏｓｃｏｐｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
BR112019022447A2 (pt) 2017-04-27 2020-06-09 Bober Miroslaw sistema e método para análise de imagem funduscópica automatizada
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
CR20190559A (es) 2017-05-18 2020-02-10 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores del receptor de pge2
LT3625228T (lt) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd Pirimidino dariniai, kaip pge2 receptoriaus moduliatoriai
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
EP3638265A4 (en) * 2017-06-15 2021-04-14 University of North Texas Health Science Center REPROGRAMMATION OF FIBROBLASTS IN RETINAL CELLS
KR20200042912A (ko) * 2017-08-20 2020-04-24 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 녹내장을 치료하기 위한 Wnt5a의 조절
EP3773638A4 (en) * 2018-04-06 2022-04-06 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR TREATING LOSS OF VISION BY GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS
EP3937955A4 (en) * 2019-03-15 2022-12-07 The Schepens Eye Research Institute, Inc. ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜
US20230034053A1 (en) * 2019-09-25 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
ATE303383T1 (de) 1999-12-17 2005-09-15 Chiron Corp Bizyklische inhibitoren von glycogen synthase kinase 3
EP1317433A2 (en) 2000-09-06 2003-06-11 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BRPI0113757B1 (pt) 2000-09-11 2017-05-23 Chiron Corp derivados de quinolinona como inibibores de tirosina quinase
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
JP4656838B2 (ja) 2002-02-06 2011-03-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
EP1490093A4 (en) 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic METHOD AND COMPOSITIONS FOR TREATING ISCHEMIA
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
WO2004037791A1 (en) 2002-10-21 2004-05-06 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1831119B (zh) * 2003-05-02 2010-05-26 斯克里普斯研究学院 造血干细胞及其治疗新生血管性眼疾的方法
MXPA05013637A (es) 2003-08-13 2006-02-24 Chiron Corp Inhibidores gsk-3 y usos de los mismos.
KR101309500B1 (ko) * 2004-09-03 2013-09-24 더 스크립스 리서치 인스티튜트 분리된 계통 음성 조혈 줄기세포 및 이를 사용한 치료 방법
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2599172A1 (en) 2005-02-24 2006-08-31 The Scripps Research Institute Method for the treatment of retinopathy of prematurity and related retinopathic diseases
PT1888123E (pt) * 2005-06-08 2013-03-13 Janssen Biotech Inc Uma terapêutica celular para a degeneração ocular
WO2008156728A1 (en) * 2007-06-15 2008-12-24 Neuronyx, Inc. Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
GB0816577D0 (en) * 2008-09-11 2008-10-15 Axordia Ltd Growth factor
KR101268741B1 (ko) * 2009-10-06 2013-06-04 김지연 줄기세포를 망막세포로 분화시키는 방법

Also Published As

Publication number Publication date
IL230830A0 (en) 2014-03-31
BR112014002718A2 (pt) 2017-06-13
WO2013020945A1 (en) 2013-02-14
EP2739723A1 (en) 2014-06-11
RU2014108478A (ru) 2015-09-10
MX2014001475A (es) 2014-07-22
NZ621345A (en) 2015-09-25
SG2014008080A (en) 2014-03-28
CA2844106A1 (en) 2013-02-14
AU2012293681A1 (en) 2014-03-06
AR087471A1 (es) 2014-03-26
JP2014527407A (ja) 2014-10-16
WO2013020945A9 (en) 2013-04-04
EP2554662A1 (en) 2013-02-06
CN104011203A (zh) 2014-08-27
KR20140068936A (ko) 2014-06-09
US20140199277A1 (en) 2014-07-17
CO7081142A2 (es) 2014-10-10

Similar Documents

Publication Publication Date Title
BR112014002718A2 (pt) célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BR112014020121A2 (pt) bandeja para uso em uma subarmação de uma armação, métodos para usar uma bandeja e para usar uma subarmação, e, subarmação
BR112013019083A2 (pt) combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
EP2701700A4 (en) PHARMACEUTICAL THERAPY FOR INHIBITING CHEMOTHERAPY-INDUCED SIDE EFFECTS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHOD AND KITS
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
BR112013022883A2 (pt) aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]